ArticleBreast cancer (Tokyo, Japan)2026
Exploring the prognostic value and biomarker of TEX11 in breast cancer via PANoptosis.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBreast cancer (BRCA) is substantial risk to human health and life. Studies have shown that PANoptosis and explores relationship between PANoptosis and BRCA patient's prognosis.
methodsThe TCGA-BRCA cohort and GSE7390 dataset were analyzed to investigate 19 PANoptosis-related genes (PRGs). Differentially expressed genes (DEGs 1) between BRCA and normal samples were identified, and Weighted Gene Co-expression Network Analysis (WGCNA) was applied to select genes most correlated with the PANoptosis score. Key module genes were intersected with DEGs 1, and candidate genes were determined using Kaplan-Meier analysis, stratifying BRCA samples into high- and low-expression groups. TEX11-related DEGs were further explored. Prognostic candidate genes were screened via univariate Cox and LASSO regression, and final independent prognostic factors were confirmed through univariate and multivariate Cox analyses.
resultsThe 578 intersection genes were acquired via taking intersection of 5,044 DEGs 1 and 1,947 key module genes. TEX11 was subsequently selected for further analysis among these. TEX11 expression levels classify BRCA patients into a high and low group. According to GSEA, regulation of T cell-mediated cytotoxicity was concentrated in the TEX11 high group. 14 differential immune cells were identified, and TEX11 was positively relevant to M1 Macrophages. Next, nine immune checkpoints and TIDE scores in high-expression group showed an upward trend. Moreover, 18 drugs were significant differences between two expression groups, such as Gemcitabine. Finally, 5 biomarkers and 3 independent prognostic factors were identified.
conclusionThis study established TEX11 as important gene related to prognosis of BRCA, identified five related BRCA biomarkers, highlighted three independent prognostic factors.
Indexed as
Identifiers
41182569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.